-
公开(公告)号:EP3132792B1
公开(公告)日:2019-09-11
申请号:EP16179626.3
申请日:2006-11-20
IPC分类号: A61K31/00 , A61K31/135 , A61K31/138 , A61K31/423 , A61K31/4525 , A61K31/485 , A61K31/55 , A61K31/551 , A61K31/7048 , A61K45/06 , A61P3/10 , A61K38/28 , A61K31/445 , A61K31/519 , A61K31/5415 , A61K31/5513 , A61K31/554 , A61K31/35 , A61K31/137 , A61K31/357
-
公开(公告)号:EP3281628B1
公开(公告)日:2019-09-11
申请号:EP17175080.5
申请日:2004-04-21
IPC分类号: A61K31/485 , A61K31/137 , A61P3/04 , A61K45/06
-
公开(公告)号:EP3659604A1
公开(公告)日:2020-06-03
申请号:EP19199374.0
申请日:2011-01-10
IPC分类号: A61K31/485 , A61K31/137 , A61P3/04
摘要: Disclosed are methods of providing weight loss therapy, particularly for patients suffering from major depression.
-
公开(公告)号:EP3626236A1
公开(公告)日:2020-03-25
申请号:EP19186587.2
申请日:2007-05-31
IPC分类号: A61K31/135 , A61K31/137 , A61K31/485 , A61K9/20
摘要: A sustained-release oral dosage form of naltrexone or a pharmaceutically acceptable salt thereof is provided. The oral dosage form may be administered with another compound. Administration of the oral dosage form may reduce a side effect, which may be a side effect at least partially attributable to a weight-loss treatment. The oral dosage form may be administered to treat a weight-loss condition.
-
公开(公告)号:EP2061448B1
公开(公告)日:2019-07-17
申请号:EP07795652.2
申请日:2007-05-31
IPC分类号: A61K31/135 , A61K31/137 , A61K31/485 , A61K9/20
-
-
-
-